Setting: Elias’s Office
The glow of the Fateweaver’s data streams painted the room in shifting blues and greens, casting Elias’s face in sharp relief.
Layla Reed stood at his side, clutching her tablet like a shield. Her usually confident demeanor was tinged with uncertainty as she scanned the glowing web of probabilities before them.
“This isn’t just market manipulation,” she said, her voice low. “We’re tampering with scientific discovery itself.”
Elias’s gaze never wavered from the holographic projection in front of him, a swirling nexus of interconnected probabilities centered around Biomera Pharma.
“We’re accelerating progress,” he replied, his tone devoid of doubt. “VX-203 could save millions of lives. The fact that we stand to profit is incidental.”
Layla shot him a sharp look. “Incidental? We’ve invested billions. That’s not exactly altruism.”
Elias finally turned to face her, his eyes cold and calculating. “The world doesn’t move without leverage, Layla. Philanthropy is inefficient. Control is absolute.”
The hologram zoomed in, highlighting a critical juncture in the pharmaceutical company’s research pipeline.
“They’re close,” Elias explained, pointing to the live feed of molecular simulations. “But the current formulation is unstable. The trials will collapse within weeks unless they pivot to an alternate synthesis pathway.”
Layla frowned. “Then why haven’t they?”
“Dr. Kara Sloane,” Elias said, her name hanging in the air like a verdict. “She’s brilliant but cautious and too focused on incremental adjustments to see the bigger picture.”
Layla crossed her arms. “So, what’s the plan? Push her to take the leap?”
Elias allowed himself a faint smile. “Precisely. The Fateweaver has mapped out three pivotal moments. Each one will subtly guide her toward the solution. It’s not about forcing her hand, it's about making the right choice inevitable.”
The Machine projected a timeline, its precision mesmerizing. Elias gestured, and the hologram split into three distinct nodes:
1. The Catalyst: A recently published paper on molecular stability from a rival lab needed to reach Dr. Sloane.
This narrative has been purloined without the author's approval. Report any appearances on Amazon.
2. The Pressure Point: A key investor in Biomera would express concerns about the delays, subtly encouraging urgency.
3. The Whisper: An internal memo from a trusted colleague would propose the exact alternate pathway needed for success.
Layla stared at the glowing probabilities, her stomach tightening. “And how do we pull all this off without them realizing they’re being manipulated?”
Elias’s smirk widened. “By letting them believe they’re acting of their own volition. The weaver handles the rest.”
The room fell silent as the Fateweaver’s hum deepened, its algorithms weaving unseen threads through reality.
The paper was subtly promoted within Biomera’s internal research network, flagged as “highly relevant” by a well-placed consultant in their analytics division.
A scheduled call between Biomera’s CEO and their largest investor was rerouted through a carefully curated briefing, planting the seed of urgency.
Sloane's trusted colleague, Dr. Rajan Malik, received a “suggested” memo drafted by Elias’s team, encouraging him to advocate for the alternate pathway during the next research meeting.
Within hours, the first ripples began to manifest.
Two days later, Layla stood in the observation deck, watching as Biomera Pharma’s research team streamed live updates. The atmosphere in their lab was electric.
“They’re pivoting,” Layla said, almost to herself, as she read the updates on her tablet. “Dr. Sloane proposed the synthesis pathway this morning. They’ve already seen a 40% improvement in stability tests.”
Elias joined her, his presence quiet yet commanding. “And the trials?”
“On track,” she replied. “If the adjustments hold, they’ll report breakthrough results within a week.”
Elias nodded, his expression unreadable. “Good. Let the world think they’ve achieved this on their own.”
Layla turned to him, her eyes searching. “Do you ever feel the weight of it? Knowing you’re pulling strings that decide the course of lives?”
Elias didn’t answer immediately. He stared out at the city, his voice a quiet rumble.
“Every action creates ripples, Layla. The difference is, we know where ours will lead.”
A week later, Biomera Pharma’s stock soared as news broke of VX-203’s unprecedented success. The vaccine’s stability and efficacy exceeded expectations, heralding a new era in antiviral treatments.
Elias and Layla watched the news from his office, the glow of the screen reflecting in their faces.
“We’ve just made billions,” Layla said, her voice flat. “And saved millions of lives.”
Elias glanced at her, his gaze sharp. “Exactly as intended.”
She hesitated, then asked, “But what happens when someone discovers what we’re doing? That we’re rewriting probabilities to serve our own ends?”
Elias turned back to the screen, his expression impassive. “Then we’ll adapt. Like we always do.”
---